DELMAR, PAUL P,‧德爾馬,FOERNZLER, DOROTHEE D,‧福恩茲勒,SCHERER, STEFAN S,‧謝勒
申请号：
HK15109509.8
公开号：
HK1208804A
申请日:
2013.04.03
申请国别(地区):
HK
年份:
2016
代理人:
摘要：
The present invention provides methods for improving the progression- free survival of a patient suffering from gastrointestinal cancer, in particular, metastatic colorectal cancer (mCRC), by treatment with bevacizumab (Avastin TM ) in combination with a chemotherapy regimen by determining the expression level of one or more of VEGFA, HER2 and neuropilin relative to control levels in patients diagnosed with gastrointestinal cancer, in particular, metastatic colorectal cancer (mCRC). The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin TM ) in combination with a chemotherapy regimen, by determining the expression level of one or more of VEGFA, HER2 and neuropilin relative to control levels in patients diagnosed with gastrointestinal cancer, in particular, metastatic colorectal cancer (mCRC).
